Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Galea

Showing results (111-120 of 116) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 116 results.
European Journal of Neurology|April 3, 2024
Real-world persistence of multiple sclerosis disease-modifying therapiesEmma C Tallantyre, Ruth Dobson, Joseph L J Froud, et al.
The Lancet. Child & Adolescent Health|July 17, 2021
Neurological manifestations of SARS-CoV-2 infection in hospitalised children and adolescents in the UK: a prospective national cohort studyStephen T J Ray, Omar Abdel-Mannan, Mario Sa, et al.
Brain Communications|August 19, 2021
Spectrum, risk factors and outcomes of neurological and psychiatric complications of COVID-19: a UK-wide cross-sectional surveillance studyAmy L Ross Russell, Marc Hardwick, Athavan Jeyanantham, et al.
Lancet (London, England)|October 4, 2025
Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trialJeremy Chataway, Thomas Williams, James Blackstone, et al.
BMJ Open|September 16, 2024
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UKJames Blackstone, Thomas Williams, Jennifer M Nicholas, et al.
Health Technology Assessment (Winchester, England)|June 29, 2026
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trialThomas Williams, James Blackstone, Nevin John, et al.
Pageof 12

Showing results (111-120 of 116) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 116 results.
European Journal of Neurology|April 3, 2024
Real-world persistence of multiple sclerosis disease-modifying therapiesEmma C Tallantyre, Ruth Dobson, Joseph L J Froud, et al.
The Lancet. Child & Adolescent Health|July 17, 2021
Neurological manifestations of SARS-CoV-2 infection in hospitalised children and adolescents in the UK: a prospective national cohort studyStephen T J Ray, Omar Abdel-Mannan, Mario Sa, et al.
Brain Communications|August 19, 2021
Spectrum, risk factors and outcomes of neurological and psychiatric complications of COVID-19: a UK-wide cross-sectional surveillance studyAmy L Ross Russell, Marc Hardwick, Athavan Jeyanantham, et al.
Lancet (London, England)|October 4, 2025
Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trialJeremy Chataway, Thomas Williams, James Blackstone, et al.
BMJ Open|September 16, 2024
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UKJames Blackstone, Thomas Williams, Jennifer M Nicholas, et al.
Health Technology Assessment (Winchester, England)|June 29, 2026
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trialThomas Williams, James Blackstone, Nevin John, et al.
Pageof 12